Liquidia Technologies Inc (LQDA)vsViatris Inc (VTRS)
LQDA
Liquidia Technologies Inc
$75.49
-1.10%
HEALTHCARE · Cap: $6.33B
VTRS
Viatris Inc
$15.38
-0.13%
HEALTHCARE · Cap: $19.19B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 4955% more annual revenue ($14.56B vs $288.06M). LQDA leads profitability with a 7.7% profit margin vs -2.0%. LQDA earns a higher WallStSmart Score of 54/100 (C-).
LQDA
Buy54
out of 100
Grade: C-
VTRS
Buy50
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 46.3%
Revenue surging 4159.0% year-over-year
Every $100 of equity generates 28 in profit
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
7.7% margin — thin
Elevated debt levels
Premium valuation, high expectations priced in
ROE of -2.0% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : LQDA
The strongest argument for LQDA centers on Operating Margin, Revenue Growth, Return on Equity. Revenue growth of 4159.0% demonstrates continued momentum.
Bull Case : VTRS
The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.
Bear Case : LQDA
The primary concerns for LQDA are EPS Growth, Profit Margin, Debt/Equity. A P/E of 419.0x leaves little room for execution misses. Debt-to-equity of 1.70 is elevated, increasing financial risk.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
LQDA profiles as a hypergrowth stock while VTRS is a turnaround play — different risk/reward profiles.
VTRS carries more volatility with a beta of 0.90 — expect wider price swings.
LQDA is growing revenue faster at 4159.0% — sustainability is the question.
VTRS generates stronger free cash flow (348M), providing more financial flexibility.
Bottom Line
LQDA scores higher overall (54/100 vs 50/100) and 4159.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Liquidia Technologies Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and markets various products for the unmet needs of patients in the United States. The company is headquartered in Morrisville, North Carolina.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?